KPV

Research Overview

KPV serves as a valuable research tool for investigating non-receptor-mediated anti-inflammatory mechanisms. This synthetic tripeptide represents the C-terminal sequence of α-MSH (Lys-Pro-Val) and retains potent anti-inflammatory activity despite lacking the full melanocortin sequence required for receptor binding. Full melanocortin receptor agonism is investigated using Melanotan 2, which targets MC-1R through MC-4R for studying the complete melanocortin signaling spectrum. Research applications span inflammatory pathway investigation, intestinal inflammation models, antimicrobial activity studies, and wound healing research. Anti-inflammatory peptide research positions KPV alongside LL-37, which bridges innate immune defense with inflammation modulation, and BPC-157, which promotes tissue healing through growth factor and nitric oxide pathway activation.

The peptide’s designation as KPV derives from single-letter amino acid codes for its constituent amino acids. Unlike full-length α-MSH or synthetic melanocortin analogs that exert effects through melanocortin receptor activation, KPV demonstrates anti-inflammatory activity through direct intracellular mechanisms, particularly NF-κB (nuclear factor kappa B) pathway inhibition.

KPV research has contributed significantly to understanding non-classical anti-inflammatory peptide mechanisms. The tripeptide’s small size allows for efficient cellular penetration and direct interaction with intracellular inflammatory signaling components. This unique mechanism of action provides complementary research approaches to receptor-mediated anti-inflammatory pathways.

Molecular Characteristics

Complete Specifications:

• CAS Registry Number: 79147-07-0
• Molecular Weight: 341.45 Da
• Molecular Formula: C₁₆H₃₀N₄O₄
• Amino Acid Sequence: Lys-Pro-Val (H-Lys-Pro-Val-OH)
• PubChem CID: 9938004
• Peptide Classification: Synthetic tripeptide, anti-inflammatory peptide
• Appearance: White to off-white powder
• Solubility: Water, phosphate buffered saline, cell culture media

The peptide’s three-amino acid structure provides exceptional stability and cellular penetration properties. The lysine residue confers positive charge at physiological pH, facilitating cellular uptake. Proline’s cyclic structure and valine’s branched hydrophobic side chain contribute to peptide stability and resistance to enzymatic degradation. The small molecular size enables penetration through cell membranes and access to intracellular targets.

Pharmacokinetic Profile in Research Models

KPV pharmacokinetic characterization in preclinical research reveals important properties for experimental design:

Absorption and Bioavailability:

• Enhanced cellular penetration compared to larger peptides
• Multiple administration routes investigated: oral, topical, subcutaneous, intraperitoneal
• Oral bioavailability demonstrated in gastrointestinal research models
• Topical application shows local anti-inflammatory effects

Distribution and Elimination:

• Plasma half-life: Relatively short (minutes to hours) due to small size
• Rapid cellular uptake and distribution
• Tissue penetration to sites of inflammation
• Intracellular accumulation at inflammatory foci

Pharmacodynamic Characteristics:

• Onset of anti-inflammatory effects: 1-6 hours post-administration in research models
• Duration of effects: 6-24 hours depending on model and amount
• concentration-dependent NF-κB inhibition
• Local effects following topical administration

These pharmacokinetic properties inform research protocol design, particularly regarding administration routes, administration frequency, and timing of inflammatory measurements.

Research Applications

Anti-Inflammatory Mechanism Studies

KPV serves as a primary research tool for investigating non-receptor-mediated anti-inflammatory pathways:

• NF-κB Inhibition Research: Investigation of KPV’s direct inhibition of nuclear factor kappa B translocation and inflammatory gene transcription
• Cytokine Modulation Studies: Examination of effects on pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8) and anti-inflammatory mediators
• Inflammatory Signaling Pathways: Research on MAPK pathways, AP-1 transcription factors, and other inflammatory signaling cascades
• Oxidative Stress Studies: Investigation of antioxidant effects and reactive oxygen species (ROS) modulation
• Inflammatory Gene Expression: Analysis of inflammatory gene transcription, mRNA stability, and protein expression

Research protocols employ cell culture inflammatory models, cytokine assays, NF-κB reporter assays, and gene expression analysis to characterize KPV’s anti-inflammatory mechanisms.

Gastrointestinal Inflammation Research

Given KPV’s origin from α-MSH and demonstrated oral activity, substantial research focuses on intestinal inflammation:

• Inflammatory Bowel Disease Models: Investigation of KPV effects in experimental colitis models (DSS, TNBS, etc.)
• Intestinal Barrier Function: Research on gut permeability, tight junction integrity, and epithelial barrier maintenance
• Mucosal Immune Response: Studies on intestinal immune cell populations, mucosal inflammation, and local immune regulation
• Colonic Inflammation Biomarkers: Examination of inflammatory markers, histological damage scores, and disease activity indices
• Oral Administration Studies: Research on oral bioavailability, local gastrointestinal effects, and systemic anti-inflammatory activity

Laboratory studies utilize inflammatory bowel disease animal models, intestinal epithelial cell cultures, and ex vivo intestinal tissue preparations.

Antimicrobial Activity Research

KPV demonstrates antimicrobial peptide properties:

• Bacterial Growth Inhibition: Investigation of antibacterial activity against gram-positive and gram-negative bacteria
• Mechanism of Antimicrobial Action: Research on membrane disruption, bacterial cell wall interactions, and intracellular antimicrobial effects
• Biofilm Studies: Examination of effects on bacterial biofilm formation and disruption
• Pathogen-Specific Activity: Studies on activity against specific pathogens relevant to inflammatory conditions
• Synergy Studies: Investigation of combined effects with other antimicrobial agents or anti-inflammatory compounds

Research protocols include minimum inhibitory concentration (MIC) assays, bacterial culture studies, biofilm quantification, and mechanism-of-action investigations.

Wound Healing and Tissue Repair Research

KPV research extends to tissue repair applications:

• Wound Healing Models: Investigation of effects on acute and chronic wound healing processes
• Inflammation Resolution: Studies on inflammatory phase modulation and transition to tissue repair
• Cellular Migration Research: Examination of keratinocyte and fibroblast migration during wound healing
• Collagen Synthesis Studies: Research on extracellular matrix formation and remodeling
• Angiogenesis Investigation: Analysis of blood vessel formation supporting tissue repair

Laboratory models include in vitro scratch assays, wound healing animal models, and tissue repair biomarker measurements.

Skin Inflammation and Dermatological Research

Research applications in dermatology and skin biology:

• Topical Anti-Inflammatory Effects: Investigation of local skin inflammation modulation
• Skin Barrier Function: Research on epidermal barrier integrity and skin permeability
• Dermatitis Models: Studies in atopic dermatitis, contact dermatitis, and other inflammatory skin conditions
• Psoriasis Research: Investigation of effects in psoriasis models with keratinocyte hyperproliferation and inflammation
• Skin Immune Response: Examination of skin-resident immune cells and cutaneous immune regulation

Research protocols employ dermatitis animal models, cultured keratinocytes, skin explants, and topical application studies.

Laboratory Handling and Storage Protocols

Powder Storage:

• Store at -20°C to -80°C in original sealed container
• Desiccated storage environment recommended
• Protect from moisture exposure
• Stability data available for 24+ months at -20°C

Handling Considerations:
KPV’s small size and stability allow for flexible handling. The peptide tolerates freeze-thaw cycles better than larger peptides and maintains activity across physiological pH range (6.5-8.0).

Quality Assurance and Analytical Testing

Each KPV batch undergoes comprehensive analytical characterization:

Purity Analysis:

• High-Performance Liquid Chromatography (HPLC): ≥99% purity
• Analytical method: Reversed-phase HPLC with UV detection at 220nm
• Multiple peak integration to ensure accurate purity determination

Structural Verification:

• Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms molecular weight 341.45 Da
• Amino acid analysis: Verifies sequence composition (Lys-Pro-Val)
• Peptide content determination: Quantifies actual peptide content by weight

Contaminant Testing:

• Bacterial endotoxin: <5 EU/mg (LAL method)
• Heavy metals: Below detection limits per USP standards
• Residual solvents: Within acceptable limits
• Water content: Karl Fischer titration (<10% for small peptides)

Documentation:

• Certificate of Analysis (COA) provided with each batch
• Third-party analytical verification available upon request
• Stability data documented for recommended storage conditions
• Batch-specific QC results traceable by lot number

Research Considerations

Experimental Design Factors:

Researchers should consider several factors when designing KPV experiments:

1. Concentration Selection: Determine appropriate concentrations based on inflammatory model and research objectives. Published research reports concentration ranges from micromolar (1-100 μM) in cell culture to mg/kg amounts in animal studies.

2. Administration Route: Select route based on research questions. Oral administration for gastrointestinal studies, topical for skin inflammation, systemic (IP, SC) for broader inflammatory models.

3. Timing Considerations: KPV demonstrates relatively rapid onset of anti-inflammatory effects. Design experiments with appropriate pre-treatment timing or therapeutic timing relative to inflammatory stimulus.

4. Non-Receptor Mechanism: Unlike melanocortin receptor agonists, KPV’s mechanism involves direct intracellular effects. Consider mechanistic approaches targeting NF-κB and intracellular pathways.

5. Control Groups: Include appropriate vehicle controls, positive controls (corticosteroids, other anti-inflammatory agents), and comparative melanocortin peptides to distinguish receptor vs. non-receptor mechanisms.

Mechanism Investigation:

KPV’s primary anti-inflammatory mechanisms involve:

• Direct NF-κB inhibition (prevents p65 nuclear translocation)
• IκB-α degradation prevention
• Inflammatory gene transcription suppression
• Pro-inflammatory cytokine reduction (TNF-α, IL-6, IL-1β)
• Oxidative stress reduction

Secondary mechanisms include:

• Antimicrobial activity
• Cellular migration modulation
• Tissue repair pathway influences
• Barrier function enhancement

Compliance and Safety Information

Regulatory Status:
KPV is provided as a research chemical for in-vitro laboratory studies and preclinical research only. This product has not been approved by the FDA for human therapeutic use, diagnostic purposes, or medical applications.

Intended Use:

• In-vitro cell culture studies
• In-vivo preclinical research in approved animal models
• Laboratory investigation of anti-inflammatory mechanisms
• Academic and institutional research applications

NOT Intended For:

• Human consumption or administration
• Therapeutic treatment of inflammatory conditions
• Diagnostic purposes
• Dietary supplementation
• Veterinary therapeutic applications without appropriate oversight
• Any medical applications

Safety Protocols:
Researchers should follow standard laboratory safety practices when handling KPV:

• Use appropriate personal protective equipment (lab coat, gloves, safety glasses)
• Handle in well-ventilated areas
• Follow institutional biosafety guidelines
• Dispose of waste according to local regulations for biological/chemical waste
• Consult material safety data sheet (MSDS) for additional safety information

—